TABLE 1.

Pharmacokinetic parameters

AnalyteParameteraMean value ± SD (range) for group
Normal renal function (n = 6)Chronic kidney disease (n = 3)
SystemicCSFSystemicCSF
AcyclovirCmax (μM)42 ± 6.8 (33-49)7.8 ± 1.5 (4.9-8.7)82 ± 24 (55-101)16 ± 4.9 (11-21)
tmax (h)2.1 ± 0.492.3 ± 2.22.0 ± 05.3 ± 2.3
AUCτ (h·μM)137 ± 18 (118-161)37 ± 7.5 (25-44)577 ± 195 (376-765)159 ± 46 (119-210)
CL/F (ml/min)759 ± 100 (638-873)145 ± 54 (101-205)
CMMGCmax (μM)4.1 ± 1.1 (2.5-5.1)0.095 ± 0.046 (0.034-0.16)15 ± 7.0 (7.1-21)0.37 ± 0.20 (0.17-0.58)
tmax (h)3.3 ± 0.521.8 ± 2.04.3 ± 1.56.7 ± 1.2
AUCτ (h·μM)17 ± 4.1 (11-22)0.42 ± 0.21 (0.17-0.79)148 ± 66 (78-207)3.8 ± 2.0 (1.8-5.8)
8-OH-ACVCmax (μM)0.32 ± 0.10 (0.22-0.46)0.062 ± 0.014 (0.050-0.089)1.6 ± 0.57 (0.97-2.1)0.29 ± 0.080 (0.21-0.38)
tmax (h)3.5 ± 0.552.4 ± 1.54.0 ± 07.0 ± 4.6
AUCτ (h·μM)1.4 ± 0.38 (0.96-1.9)0.34 ± 0.070 (0.27-0.48)17 ± 5.6 (11-22)3.1 ± 0.94 (2.2-4.1)
  • a τ is the dosing interval (0 to 6 h for normal renal function and 0 to 12 h for renal impairment).